Dactolisib (BEZ235)

Name: Dactolisib (BEZ235)
Brand: Selleck Chemicals
SKU: S1009
Rating: 5 (286 reviews)

For research use only.

Catalog No.S1009 Synonyms: NVP-BEZ235

286 publications

Molecular Weight(MW): 469.55

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.

Selleck's Dactolisib (BEZ235) has been cited by 286 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7718):372-376

PubMed: 30046109 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Cancer Cell, 2017, 31(3):424-435

PubMed: 28292440 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nature, 2014, 30;514(7524):628-32.

PubMed: 25119024 ( click the link to review the publication )

Nature, 2012, 26;487(7408):505-9.

PubMed: 22763448 ( click the link to review the publication )

Cell, 2012, 13;149(2):307-21.

PubMed: 22500798 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1825

PubMed: 32286280 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Biomaterials, 2020, 246:120012

PubMed: 32276198 ( click the link to review the publication )

Theranostics, 2020, 16;10(14):6448-6466

PubMed: 32483463 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1255-y

PubMed: 32157217 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32085396 ( click the link to review the publication )

Cell Death Dis, 2020, 29;11(5):406

PubMed: 32471991 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):479-489

PubMed: 31672764 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.1131.2019

PubMed: 32371585 ( click the link to review the publication )

J Cancer, 2020, 11(9):2552-2559

PubMed: 32201525 ( click the link to review the publication )

Front Cell Neurosci, 2020, 15;14:134

PubMed: 32477073 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )
BMC Cancer, 2020, 20(1):4

PubMed: 31898540 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Mol Biol Rep, 2020, 47(3):2217-2230

PubMed: 32088816 ( click the link to review the publication )

J BUON, 2020, 020;25(1):464-471

PubMed: 32277670 ( click the link to review the publication )

Nanoscale Res Lett, 2020, 15(1):63

PubMed: 32219609 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):329-342

PubMed: 31912229 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Biomaterials, 2020, 230:119618

PubMed: 31757530 ( click the link to review the publication )

Clin Transl Med, 2020, 9(1):22

PubMed: 32112175 ( click the link to review the publication )

Gastroenterology, 2019, 10.1053/j.gastro.2019.11.013

PubMed: 31734182 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Cell Rep, 2019, 26(3):608-623

PubMed: 30650355 ( click the link to review the publication )

Cell Death Differ, 2019, 26(9):1670-1687

PubMed: 30683918 ( click the link to review the publication )

Radiology, 2019, 10.1148/radiol.2019190115

PubMed: 31335281 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4063-4078

PubMed: 30952635 ( click the link to review the publication )

Cancers, 2019, 11(2)

PubMed: 30813295 ( click the link to review the publication )

Cancers, 2019, 11(5)

PubMed: 31121848 ( click the link to review the publication )

Biomacromolecules, 2019, 20(9):3313-3323

PubMed: 31198025 ( click the link to review the publication )
J Dent Res, 2019, 98(3):304-312

PubMed: 30513244 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31289138 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

J Cancer, 2019, 10(5):1197-1208

PubMed: 30854129 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(1):145-159

PubMed: 30755818 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:336

PubMed: 31871431 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18249-18261

PubMed: 30851074 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:7933-7951

PubMed: 31686909 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

BMC Cancer, 2019, 20(1):1

PubMed: 31892356 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):404-416

PubMed: 30550927 ( click the link to review the publication )

Am J Transl Res, 2019, 11(1):87-105

PubMed: 30787971 ( click the link to review the publication )

Int J Mol Med, 2019, 43(1):47-56

PubMed: 30387804 ( click the link to review the publication )

Vet Comp Oncol, 2019, 10.1111/vco.12490

PubMed: 31069942 ( click the link to review the publication )

Pharm Biol, 2019, 57(1):412-423

PubMed: 31230505 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3745-3755

PubMed: 31262901 ( click the link to review the publication )

Ren Fail, 2019, 41(1):267-277

PubMed: 30982374 ( click the link to review the publication )

Assay Drug Dev Technol, 2019, 17(3):140-149

PubMed: 30958703 ( click the link to review the publication )

Nagoya J Med Sci, 2019, 81(1):93-102

PubMed: 30962658 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Viruses, 2019, 11(3)

PubMed: 30875748 ( click the link to review the publication )
Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Radiology, 2018, 288(3):730-738

PubMed: 29737948 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

J Pathol, 2018, 245(1):101-113

PubMed: 29443392 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30563275 ( click the link to review the publication )

Cancers, 2018, 10(2)

PubMed: 29370086 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):45

PubMed: 29352118 ( click the link to review the publication )

J Cancer, 2018, 9(6):987-997

PubMed: 29581778 ( click the link to review the publication )

Glia, 2018, 66(5):999-1015

PubMed: 29392777 ( click the link to review the publication )

Exp Mol Med, 2018, 50(3):e463

PubMed: 29869624 ( click the link to review the publication )

Radiat Oncol, 2018, 13(1):76

PubMed: 29685176 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )

Antiviral Res, 2018, 153:39-48

PubMed: 29425831 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )
Invest New Drugs, 2018, 10.1007/s10637-018-0698-2

PubMed: 30456603 ( click the link to review the publication )

Int J Hyperthermia, 2018, 34(6):812-823

PubMed: 28954551 ( click the link to review the publication )

Cancer Med, 2018, 7(9):4744-4754

PubMed: 30109783 ( click the link to review the publication )

Am J Transl Res, 2018, 10(12):4376-4384

PubMed: 30662679 ( click the link to review the publication )

Oncol Rep, 2018, 39(2):711-720

PubMed: 29207150 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2353-2362

PubMed: 30066933 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1731-1738

PubMed: 29393465 ( click the link to review the publication )

J Cell Biochem, 2018, 119(3):2708-2718

PubMed: 29057547 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2461-2472

PubMed: 29436587 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2755-2763

PubMed: 29436606 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190854

PubMed: 29357370 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 495(2):2004-2009

PubMed: 29253572 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 504(4):721-726

PubMed: 30217442 ( click the link to review the publication )

Anticancer Res, 2018, 38(3):1407-1414

PubMed: 29491065 ( click the link to review the publication )

Pathol Res Pract, 2018, 214(6):889-895

PubMed: 29653746 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):9655-9662

PubMed: 29928341 ( click the link to review the publication )

Oncotarget, 2018, 9(6):7023-7035

PubMed: 29467947 ( click the link to review the publication )

Sci Rep, 2018, 8(1):1652

PubMed: 29374181 ( click the link to review the publication )

Discov Med, 2018, 25(140):265-275

PubMed: 30021100 ( click the link to review the publication )

Mol Cell, 2017, 65(6):999-1013

PubMed: 28306514 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1636

PubMed: 29158506 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1274-1285

PubMed: 28232476 ( click the link to review the publication )
Clin Cancer Res, 2017, 23(12):3045-3052

PubMed: 28007777 ( click the link to review the publication )

Leukemia, 2017, 31(4):922-933

PubMed: 27686868 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):E1072-E1080

PubMed: 28137841 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1286-1298

PubMed: 27553832 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):9

PubMed: 28061880 ( click the link to review the publication )

Cancer Lett, 2017, 388:12-20

PubMed: 27894954 ( click the link to review the publication )

Cancer Lett, 2017, 406:1-11

PubMed: 28774796 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1779-1790

PubMed: 28619753 ( click the link to review the publication )

J Nutr Biochem, 2017, 41:124-136

PubMed: 28092744 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):467-474

PubMed: 27680680 ( click the link to review the publication )

Mol Imaging Biol, 2017, 19(3):421-428

PubMed: 27770401 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(3):382-391

PubMed: 28042875 ( click the link to review the publication )

Mol Cell Neurosci, 2017, 82:66-75

PubMed: 28461220 ( click the link to review the publication )

Cell Cycle, 2017, 16(24):2386-2395

PubMed: 28980866 ( click the link to review the publication )

World J Gastroenterol, 2017, 23(42):7551-7562

PubMed: 29204055 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1115-1126

PubMed: 28435223 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(1):209-216

PubMed: 28712871 ( click the link to review the publication )

Oncol Lett, 2017, 14(6):7970-7976

PubMed: 29250185 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5077-5087

PubMed: 29118584 ( click the link to review the publication )

Oncotarget, 2017, 8(33):53968-53977

PubMed: 28903316 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11937-11949

PubMed: 28060760 ( click the link to review the publication )
Oncotarget, 2017, 8(30):49380-49394

PubMed: 28537902 ( click the link to review the publication )

Oncotarget, 2017, 8(63):106486-106498

PubMed: 29290965 ( click the link to review the publication )

Nano Lett, 2017, 17(11):7160-7168

PubMed: 29035540 ( click the link to review the publication )

Nat Commun, 2016, 7:11971

PubMed: 27321283 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

EMBO J, 2016, 35(20):2192-2212

PubMed: 27625374 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(11):2744-54

PubMed: 26712685 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(6):643-655

PubMed: 27463366 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Mol Carcinog, 2016, 55(12):2135-2155

PubMed: 26764221 ( click the link to review the publication )

Int J Oncol, 2016, 49(1):285-93

PubMed: 27176231 ( click the link to review the publication )

Biomed Pharmacother, 2016, 77:161-6

PubMed: 26796280 ( click the link to review the publication )

BMC Cancer, 2016, 16:657

PubMed: 27542970 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:393-400

PubMed: 27620077 ( click the link to review the publication )

Cancer Med, 2016, 5(10):2953-2964

PubMed: 27539383 ( click the link to review the publication )

Transl Oncol, 2016, 9(3):197-202

PubMed: 27267837 ( click the link to review the publication )

Cell Biochem Funct, 2016, 34(2):69-81

PubMed: 26919061 ( click the link to review the publication )

Animal, 2016, 10(8):1319-27

PubMed: 26956906 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Target Oncol, 2016, 11(2):209-27

PubMed: 26453055 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )
Tumour Biol, 2016, 37(1):419-24

PubMed: 26219899 ( click the link to review the publication )

Heliyon, 2016, 2(11):e00194

PubMed: 27896318 ( click the link to review the publication )

Oncotarget, 2016, 8(32):52193-52210

PubMed: 28881723 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65147-65156

PubMed: 27556501 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13797-809

PubMed: 26883194 ( click the link to review the publication )

J Clin Invest, 2015, 125(3):1174-88

PubMed: 25664849 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(24):5499-5510

PubMed: 26272063 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Cancer Res, 2015, 75(24):5318-28

PubMed: 26670562 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.444

PubMed: 25619831 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.143

PubMed: 25961924 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Cancer Lett, 2015, 367(1):58-68

PubMed: 26188279 ( click the link to review the publication )

Cancer Lett, 2015, 359(1):47-56

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:32

PubMed: 25849721 ( click the link to review the publication )

J Neurosci, 2015, 35(9):3893-902

PubMed: 25740518 ( click the link to review the publication )

Cancer Discov, 2015, 5(12):1262-70

PubMed: 26370156 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(4):1014-23

PubMed: 25673820 ( click the link to review the publication )

Neoplasia, 2015, 17(1):16-31

PubMed: 25622896 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:65

PubMed: 26130968 ( click the link to review the publication )

J Dermatol Sci, 2015, 78(1):44-50

PubMed: 25726712 ( click the link to review the publication )

Mol Imaging Biol, 2015, 17(3):403-12

PubMed: 25465391 ( click the link to review the publication )
Cancer Biol Ther, 2015, 16(4):580-8

PubMed: 25793663 ( click the link to review the publication )

Prostate, 2015, 75(15):1747-59

PubMed: 26250606 ( click the link to review the publication )

BMC Cancer, 2015, 15:894

PubMed: 26560145 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144708

PubMed: 26678268 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:269-77

PubMed: 25674002 ( click the link to review the publication )

Biomed Res Int, 2015, 2015:870918

PubMed: 26557706 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(10):2193-8

PubMed: 26270491 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Oncotarget, 2015, 6(32):32930-43

PubMed: 26431379 ( click the link to review the publication )

EJNMMI Res, 2015, 5(1):61

PubMed: 26543028 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Nano Lett, 2015, 15(12):8032-43

PubMed: 26540670 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(2):404-12

PubMed: 24192926 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2126-35

PubMed: 24573549 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(5):1235-48

PubMed: 24366691 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.12.034

PubMed: 25554016 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 10.1111/pcmr.12268

PubMed: 24890688 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )
Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

FASEB J, 2014, fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Oncol, 2014, 8(3):544-54

PubMed: 24476679 ( click the link to review the publication )

J Virol, 2014, 88(9):5152-64

PubMed: 24574393 ( click the link to review the publication )

Magnet Reson Med, 2014, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

Apoptosis, 2014, 19(5):895-904

PubMed: 24652480 ( click the link to review the publication )

Endocrinology, 2014, 155(4):1510-9

PubMed: 24476133 ( click the link to review the publication )

Expert Opin Inv Drugs, 2014, 23(4):469-87

PubMed: 24490883 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Invest New Drugs, 2014, 32(6):1134-43

PubMed: 25152245 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

BMC Cancer, 2014, 14:283

PubMed: 24758408 ( click the link to review the publication )

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108193

PubMed: 25247710 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Cardiovasc Inter Rad, 2014, 37(5):1343-51

PubMed: 24452318 ( click the link to review the publication )

Eur Biophys J, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )
Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(11):708-14

PubMed: 24013279 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):505-13

PubMed: 23319394 ( click the link to review the publication )

Int J Cancer, 2013, 133(9):2089-101

PubMed: 23629727 ( click the link to review the publication )

Oncogene, 2013, 32(17):2179-88

PubMed: 22689062 ( click the link to review the publication )

Cancer Lett, 2013, 329(2):236-42

PubMed: 23200669 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(1):R16

PubMed: 23448424 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

J Mater Chem B, 2013, 5602-5610

PubMed: ( click the link to review the publication )

Cancer Sci, 2013, 104(7):896-903

PubMed: 23578175 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )

Magn Reson Med, 2013, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2013, 288(42):30387-98

PubMed: 24014036 ( click the link to review the publication )

Acta Pharmacol Sin, 2013, 34(5):681-90

PubMed: 23603977 ( click the link to review the publication )

Transl Oncol, 2013, 6(5):586-95

PubMed: 24151539 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59879

PubMed: 23533654 ( click the link to review the publication )

J Biomol Screen, 2013, 19(1):131-44

PubMed: 23954931 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )
Clin Cancer Res, 2012, 18(9):2515-25

PubMed: 22392911 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Oncogene, 2012, 33(2):236-45

PubMed: 23246970 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(7):1850-9

PubMed: 22437314 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

J Neurosci, 2012, 32(1):264-74

PubMed: 22219288 ( click the link to review the publication )

Neoplasia, 2012, 14(1):34-43

PubMed: 22355272 ( click the link to review the publication )

Cancer Sci, 2012, 103(11):1955-60

PubMed: 22925034 ( click the link to review the publication )

J Virol, 2012, 86(8):4578-85

PubMed: 22345463 ( click the link to review the publication )

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )

Hum Pathol, 2012, 43(12):2197-206

PubMed: 22705003 ( click the link to review the publication )

J Surg Oncol, 2012, 106(8):972-80

PubMed: 22711648 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Blood, 2011, 118(14):3911-21

PubMed: 21821710 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Breast Cancer Res, 2011, 13(3):R52

PubMed: 21595894 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(24):6029-39

PubMed: 21169255 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Cancer Res, 2010, 70(12):4982-94

PubMed: 20530683 ( click the link to review the publication )

Eur J Cancer, 2010, 46(6):1111-21

PubMed: 20129775 ( click the link to review the publication )

Biochemistry, 2010, 49(39):8488-98

PubMed: 20804212 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR (p70S6K) ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	ATR ^[8] (3T3^TopBP1-ER cells)	View More
4 nM	5 nM	6 nM	7 nM	21 nM	View More

In vitro

BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ235 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM. ^[1] BEZ235 is an mTORC1/2 catalytic inhibitor. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Trypanosoma brucei brucei	NHz3fWhCdnSrbXnjdo9jcWGuIFHzd4F6		M2TucFE5KGh?	NH;pZ2VFVVOR	M4TkeWFvfGm2conwZY5we2:vYXygZYN1cX[rdImge4l1cCCHQ{WwJI9nKDBwMECyOUDPxE1?	MlH4NlQ5ODV7NE[=
MCF7	M4HWdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX[wMlAyNTFyMDFOwG0>	NXz1V4RCPDhiaB?=	M{Tw[mROW09?	NFG2WZVKSzVyPUCuO\|Mh\|ryP	MWiyN\|g4OTlyNB?=
HCT116	NHPu[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfWNE4xOS1zMECg{txO	NITISHA1QCCq	M{Tte2ROW09?	M{HMXmlEPTB;MT6xOkDPxE1?	MmXQNlM5PzF7MES=
U87MG	M4PSfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2OweFAvODFvMUCwJO69VQ>?	NFuyRY01QCCq	MlzmSG1UVw>?	M13hb2lEPTB;MT6zNkDPxE1?	MV2yN\|g4OTlyNB?=
HBC4	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnveWh6OC5yMT2xNFAh\|ryP	MVe0PEBp		MorkUI9oKEeLNUC9MVgvPjFiTR?=	MoS1NlI{OzZ{NE[=
BSY1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;ENVAvODFvMUCwJO69VQ>?	M3TNXlQ5KGh?		NWKyc4tHVG:pIFfJOVA:NThwNEigUS=>	NX\JfG9JOjJ\|M{[yOFY>
HBC5	NYOxTVZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXqNE4xOS1zMECg{txO	NHLoPWQ1QCCq		M2nTVmxw\yCJSUWwQU04Njh5IF2=	NYj1WHhlOjJ\|M{[yOFY>
MCF7	NVXaW2FYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPoNE4xOS1zMECg{txO	M1j5eFQ5KGh?		MkmwUI9oKEeLNUC9MVgvOTZiTR?=	NVnqTpRSOjJ\|M{[yOFY>
MDA-MB-231	MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV:wMlAyNTFyMDFOwG0>	M4rxelQ5KGh?		M3vBdmxw\yCJSUWwQU05NjB7IF2=	Mn3sNlI{OzZ{NE[=
U251	M121W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HTWVAvODFvMUCwJO69VQ>?	NYP0d3E6PDhiaB?=		MXLMc4chT0l3ME2tO{43PiCP	MYeyNlM{PjJ2Nh?=
SF268	NF\WOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17IRlAvODFvMUCwJO69VQ>?	MYW0PEBp		NEPrZ29Nd2diR1m1NF0uPy57MjDN	NUDHeFlIOjJ\|M{[yOFY>
SF295	NHTEVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4ju[\|AvODFvMUCwJO69VQ>?	M3P4elQ5KGh?		MnjPUI9oKEeLNUC9MVgvOzFiTR?=	Ml;CNlI{OzZ{NE[=
SF539	NEn1UHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jEV\|AvODFvMUCwJO69VQ>?	NHTqdpE1QCCq		M{e0VGxw\yCJSUWwQU05NjV7IF2=	MYKyNlM{PjJ2Nh?=
SNB75	NHuzVZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1P1XlAvODFvMUCwJO69VQ>?	MoP5OFghcA>?		MYrMc4chT0l3ME2tPE42QCCP	Mly2NlI{OzZ{NE[=
SNB78	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MViwMlAyNTFyMDFOwG0>	NFG1T4o1QCCq		NFrGbJpNd2diR1m1NF0uQC54NTDN	NYX2dXdYOjJ\|M{[yOFY>
HCC2998	M3i1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX6ybZVKOC5yMT2xNFAh\|ryP	NIfGR2E1QCCq		M3PTdGxw\yCJSUWwQU05NjB3IF2=	Mm\BNlI{OzZ{NE[=
KM12	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYGwMlAyNTFyMDFOwG0>	NXPWPFlFPDhiaB?=		MkP0UI9oKEeLNUC9MVcvPTRiTR?=	NVzrNGZFOjJ\|M{[yOFY>
HT-29	MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYKwMlAyNTFyMDFOwG0>	M1W0XFQ5KGh?		NW[zU29xVG:pIFfJOVA:NTdwN{WgUS=>	NHzsOFczOjN\|NkK0Oi=>
HCT15	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHJN2wxNjBzLUGwNEDPxE1?	M2DrNlQ5KGh?		M1LHSmxw\yCJSUWwQU05NjB\|IF2=	MWGyNlM{PjJ2Nh?=
HCT116	M13VcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHXeJQxNjBzLUGwNEDPxE1?	M2fRSVQ5KGh?		NFjmdXlNd2diR1m1NF0uPy54MTDN	NF32N2wzOjN\|NkK0Oi=>
NCI-H23	M3LoV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfDNE4xOS1zMECg{txO	NUHYbWQ3PDhiaB?=		M1LiWGxw\yCJSUWwQU04NjZ2IF2=	MWWyNlM{PjJ2Nh?=
NCI-H226	MnPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXOwMlAyNTFyMDFOwG0>	NYfiTo9KPDhiaB?=		M1Tvd2xw\yCJSUWwQU05NjR2IF2=	MYeyNlM{PjJ2Nh?=
NCI-H522	M1rK[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWqwMlAyNTFyMDFOwG0>	MlTpOFghcA>?		MXvMc4chT0l3ME2tPE41PSCP	MkHpNlI{OzZ{NE[=
NCI-H438	NIPDcopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\nNE4xOS1zMECg{txO	NXPzXHM6PDhiaB?=		M4\scmxw\yCJSUWwQU05NjFzIF2=	NVjIXZM3OjJ\|M{[yOFY>
A549	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPjVGFCOC5yMT2xNFAh\|ryP	NYHNN5ZmPDhiaB?=		M13DfWxw\yCJSUWwQU05NjB5IF2=	M4DJVVIzOzN4MkS2
DMS273	NFfUdoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XZ[FAvODFvMUCwJO69VQ>?	NVz6dXd{PDhiaB?=		NYG3XoRRVG:pIFfJOVA:NTdwOECgUS=>	MYOyNlM{PjJ2Nh?=
DMS114	MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjUNE4xOS1zMECg{txO	NHv3dow1QCCq		MmPLUI9oKEeLNUC9MVgvOzliTR?=	M2rKNlIzOzN4MkS2
LOXIMVI	MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUS0TYkxOC5yMT2xNFAh\|ryP	M13mbVQ5KGh?		NUT5blRUVG:pIFfJOVA:NThwNk[gUS=>	NV\E[JB{OjJ\|M{[yOFY>
OVCAR3	NGW4eFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\E[Gs2OC5yMT2xNFAh\|ryP	M2fWXVQ5KGh?		M2\jUmxw\yCJSUWwQU05NjF5IF2=	MoXiNlI{OzZ{NE[=
OVCAR4	NFW5XYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3e2bVAvODFvMUCwJO69VQ>?	NUm4PXFbPDhiaB?=		NYqzbWZUVG:pIFfJOVA:NThwNUigUS=>	NUnqfHBYOjJ\|M{[yOFY>
OVCAR5	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF:5Z2kxNjBzLUGwNEDPxE1?	Mo\ZOFghcA>?		NGHEZZZNd2diR1m1NF0uPy53NzDN	MnfGNlI{OzZ{NE[=
OVCAR8	NWTySHhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13nclAvODFvMUCwJO69VQ>?	M4nwfVQ5KGh?		NVLRZ\|Y2VG:pIFfJOVA:NTdwOESgUS=>	M2DL[FIzOzN4MkS2
SKOV3	MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fkSVAvODFvMUCwJO69VQ>?	NX7VcIxKPDhiaB?=		Moj1UI9oKEeLNUC9MVgvPDFiTR?=	MX6yNlM{PjJ2Nh?=
RXF631L	MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInkbXUxNjBzLUGwNEDPxE1?	NWXOeopsPDhiaB?=		NHfvXFJNd2diR1m1NF0uQC5{MTDN	NVLlfopoOjJ\|M{[yOFY>
ACHN	M1;YV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPCZ2FDOC5yMT2xNFAh\|ryP	NX3odpdsPDhiaB?=		NYPlXW9kVG:pIFfJOVA:NTdwOUWgUS=>	MVSyNlM{PjJ2Nh?=
St-4	M1O5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjkNE4xOS1zMECg{txO	MUC0PEBp		NEThSGRNd2diR1m1NF0uPy52NzDN	NFjRXYszOjN\|NkK0Oi=>
MKN1	NXnscVJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTGTY4xNjBzLUGwNEDPxE1?	MkjhOFghcA>?		NV3EVJNSVG:pIFfJOVA:NThwNEGgUS=>	MnPzNlI{OzZ{NE[=
MKN7	M{\lOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jG[FAvODFvMUCwJO69VQ>?	MkPROFghcA>?		NIXzUI1Nd2diR1m1NF0uPy54ODDN	NV7lSZhnOjJ\|M{[yOFY>
MKN28	NIe0dmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmD0NE4xOS1zMECg{txO	NVP2SZFtPDhiaB?=		MV\Mc4chT0l3ME2tO{4xPyCP	NEnQUmIzOjN\|NkK0Oi=>
MKN45	NV3STmwzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LBd\|AvODFvMUCwJO69VQ>?	NHrQV481QCCq		NWi2TWhPVG:pIFfJOVA:NThwM{SgUS=>	MYWyNlM{PjJ2Nh?=
MKN74	NFXzeFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY[wMlAyNTFyMDFOwG0>	MVW0PEBp		Mn[zUI9oKEeLNUC9MVcvPDJiTR?=	NH7NXoQzOjN\|NkK0Oi=>
DU145	NGfMdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGKxZ5MxNjBzLUGwNEDPxE1?	M2HFN\|Q5KGh?		NUntd5lsVG:pIFfJOVA:NThwMU[gUS=>	M{j2VFIzOzN4MkS2
PC3	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUSwMlAyNTFyMDFOwG0>	NYC3ZVJ5PDhiaB?=		M4rvbWxw\yCJSUWwQU05NjZ4IF2=	NInUT5czOjN\|NkK0Oi=>
Trypanosoma brucei brucei	MoTXSpVv[3Srb36gRZN{[Xl?	NUXTRVNjOjByIH7N	MYqxNkBp	M2S2UmROW09?	MW\E[YNz\WG\|ZTDpckBxcG:\|cHjveIllgWxiaX7vd4l1d2xicHjvd5Bp[XSnIHzleoVt	NHXROm0zPDhyNUm0Oi=>
Trypanosoma brucei brucei	NFnISmpHfW6ldHnvckBCe3OjeR?=		MYSxPEBp	MonLSG1UVw>?	Mn\DTY5pcWKrdHnvckBw\iC{ZXPldJRwei2vZXTpZZRm\CCnbnTvZ5l1d3OrczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiC2cnHud4ZmenKrbjD1dJRic2V?	NX7EfoRROjR6MEW5OFY>
Trypanosoma brucei brucei	MmXPSpVv[3Srb36gRZN{[Xl?	NV\VbHV5OjByIH7N	M2O1N\|EzKGh?	Mmf2SG1UVw>?	M1y5SWVn\mWldDDvckB{eGirbnfvcZlt\WmwIHzleoVt	M{L0VlI1QDB3OUS2
Trypanosoma brucei brucei	M{HQVWZ2dmO2aX;uJGF{e2G7	MlvqNlAxKG6P	NWnH[4QyOTJiaB?=	MnTJSG1UVw>?	M4rlOGVn\mWldDDvckBxcG:\|cHjheIllgWylaH;sbY5mKGyndnXs	NF;w[pIzPDhyNUm0Oi=>
UM-UC-3	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofETWM2OD1\|MUWgdG0>	MWPTRW5ITVJ?
SBC-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorqTWM2OD15NEKgdG0>	NHv0OGhUSU6JRWK=
MKN1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjVOI1KSzVyPUKuPEBvVQ>?	MY\TRW5ITVJ?
NCI-H720	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPmWYlkUUN3ME2zMlU4KG6P	NXT5Vm9XW0GQR1XS
BFTC-909	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17jVGlEPTB;Mz63NUBvVQ>?	MUPTRW5ITVJ?
BPH-1	M2flWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTRwN{[gcm0>	MVTTRW5ITVJ?
PC-3	NF\4ZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTVwMEmgcm0>	MlX2V2FPT0WU
AN3-CA	NGGxfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWn5fHZHUUN3ME21MlU3KG6P	M1nkT3NCVkeHUh?=
HN	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DHV2lEPTB;NT65OkBvVQ>?	MVrTRW5ITVJ?
HCC2218	M4Th[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTuTWM2OD14Lk[xJI5O	NGmzOJVUSU6JRWK=
KP-4	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\kNoN6UUN3ME23JI5O	MXrTRW5ITVJ?
LU-139	NH\FS\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjuTWM2OD15Lke3JI5O	NFfoNIlUSU6JRWK=
ETK-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTvZ5ZKSzVyPUeuPFghdk1?	MVLTRW5ITVJ?
Ramos-2G6-4C10	NIPuVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRThwNEmgcm0>	NXz6VZk3W0GQR1XS
MHH-PREB-1	NIPYNXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LmfmlEPTB;OT6xNkBvVQ>?	NUiwfGs3W0GQR1XS
DU-4475	M2naNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnQSpFJUUN3ME25MlQ1KG6P	Mk[zV2FPT0WU
NCI-H1666	M4LVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\tR5J1UUN3ME25MlcyKG6P	MkDqV2FPT0WU
CAMA-1	NIfafIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTlwODDuUS=>	Ml:4V2FPT0WU
TYK-nu	M1zkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfuTZNKSzVyPUmuPVQhdk1?	NFjtW5pUSU6JRWK=
MFE-280	MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTlwOUmgcm0>	MmqzV2FPT0WU
A549	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3NPXlbUUN3ME2xNE4yPCCwTR?=	Mn2zV2FPT0WU
769-P	NF;Ld3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1f1[2lEPTB;MUCuOFQhdk1?	Mn;XV2FPT0WU
L-363	MmHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvIXGlHUUN3ME2xNE43QSCwTR?=	NEDnVppUSU6JRWK=
ES8	NH;ncXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfiTWM2OD1zMD65JI5O	Mlq5V2FPT0WU
PA-1	NVfQd2ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfBTWM2OD1zMT64NkBvVQ>?	NXfnVoJ1W0GQR1XS
Mewo	M2fuUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXL3dllFUUN3ME2xNU46QSCwTR?=	M4\4b3NCVkeHUh?=
HSC-3	NXfuPXk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTF{LkKxJI5O	NWXBS4h3W0GQR1XS
H4	NInITm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnETWM2OD1zMj62O{BvVQ>?	NIH2OXNUSU6JRWK=
BB65-RCC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HkOGlEPTB;MUKuO\|Ihdk1?	M3jFd3NCVkeHUh?=
NCI-H1793	NFfDeXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3m1SGlEPTB;MUKuPFIhdk1?	MYfTRW5ITVJ?
KARPAS-45	NI\vV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvWNI9zUUN3ME2xN{42OSCwTR?=	NHTmRWNUSU6JRWK=
GCT	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjrU\|Z{UUN3ME2xN{43QCCwTR?=	NHXpTXhUSU6JRWK=
EoL-1	Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfkTWM2OD1zMz65N{BvVQ>?	M3jLO3NCVkeHUh?=
LB2241-RCC	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkT0TWM2OD1zND6wNUBvVQ>?	NEDZbW9USU6JRWK=
ES5	NIflU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmD6TWM2OD1zND63OEBvVQ>?	Mn3LV2FPT0WU
LOXIMVI	Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTRTWM2OD1zND65PUBvVQ>?	MmXOV2FPT0WU
COR-L105	NGCz[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;ETWM2OD1zNT6wOEBvVQ>?	NFvFS5RUSU6JRWK=
P12-ICHIKAWA	MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnIV2FKSzVyPUG1MlEhdk1?	NXTyd5A{W0GQR1XS
CHL-1	NWHNdZNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFT1dY1KSzVyPUG1MlQ2KG6P	Ml\JV2FPT0WU
VMRC-RCZ	NWfHcZkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTF3Lk[zJI5O	MlnTV2FPT0WU
HH	NGflfYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTF3Lkegcm0>	MV;TRW5ITVJ?
NUGC-3	M2T2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTNTWM2OD1zNj6zOEBvVQ>?	Ml7DV2FPT0WU
EGI-1	NXrpTGx6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTF4LkSzJI5O	MWTTRW5ITVJ?
OS-RC-2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTF4LkS3JI5O	M1W1eXNCVkeHUh?=
MOLT-16	NHf6O4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3LsW2lEPTB;MUeuNVUhdk1?	M4nFUHNCVkeHUh?=
NCI-H209	M3z1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TpVWlEPTB;MUeuNlkhdk1?	MlrLV2FPT0WU
697	NITIWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljxTWM2OD1zNz60N{BvVQ>?	NY\ET4FIW0GQR1XS
D-56MG	M{[0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTF5Lk[5JI5O	M2Xae3NCVkeHUh?=
VA-ES-BJ	NGr3V5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTF5LkizJI5O	MYDTRW5ITVJ?
EW-16	NVPzfmZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTF6LkC0JI5O	MYLTRW5ITVJ?
HGC-27	NEH3WlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTF6LkC2JI5O	MX3TRW5ITVJ?
ES7	NEH0cFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUX1doJKUUN3ME2xPE4xQSCwTR?=	MmrzV2FPT0WU
HuH-7	NGXUcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7KcmZKSzVyPUG4MlQhdk1?	MWjTRW5ITVJ?
BCPAP	MnPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLwVHRKSzVyPUG4MlY2KG6P	Ml\0V2FPT0WU
SW1710	NEXxTYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXyWmVLUUN3ME2xPE44OiCwTR?=	NU[5RVJPW0GQR1XS
IST-MEL1	NYHHNXhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTF6Lke3JI5O	NYLDNmg3W0GQR1XS
SF295	M1exXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHXW29KSzVyPUG4Mlk{KG6P	NV7FNopTW0GQR1XS
RPMI-7951	M{nZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfYeXZKSzVyPUG5MlI5KG6P	MlPKV2FPT0WU
SF126	NXTkN4k1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXKUmlFUUN3ME2xPU41OSCwTR?=	NF[zNGFUSU6JRWK=
GAMG	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoryTWM2OD1zOT60PEBvVQ>?	NWn2[G1xW0GQR1XS
KNS-81-FD	M1HlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13zSGlEPTB;MUmuOVQhdk1?	MYPTRW5ITVJ?
RT-112	MnK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnPboRKSzVyPUG5MlY3KG6P	MYPTRW5ITVJ?
DEL	NWW3fVl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\5cWlEPTB;MkCuOFkhdk1?	Ml;xV2FPT0WU
CGTH-W-1	NGXkbXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTJyLk[zJI5O	NWOzPJM{W0GQR1XS
HOS	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTJzLkC2JI5O	MlnzV2FPT0WU
ES4	M3\sT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTJzLkC4JI5O	NIPOcYxUSU6JRWK=
RXF393	M{TPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\t[WlEPTB;MkGuOFUhdk1?	MWXTRW5ITVJ?
NCI-H2030	MkCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3OTHFKSzVyPUKxMlUzKG6P	MUfTRW5ITVJ?
YH-13	MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2myS2lEPTB;MkGuPFghdk1?	M{XmR3NCVkeHUh?=
HT-1080	NH;GUGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzJ[pAzUUN3ME2yNU46OyCwTR?=	NFTLV3hUSU6JRWK=
NCI-SNU-1	NHPS[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLxcoFKSzVyPUKxMlk2KG6P	M{S0ZXNCVkeHUh?=
G-402	MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4O0T2lEPTB;MkKuNVYhdk1?	NYLT[pRDW0GQR1XS
786-0	NXu1NmNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nDV2lEPTB;MkKuNlkhdk1?	MUjTRW5ITVJ?
ME-180	MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTJ{LkSzJI5O	M1jubHNCVkeHUh?=
NB69	M2fq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPMVGZRUUN3ME2yNk42OyCwTR?=	MUDTRW5ITVJ?
J-RT3-T3-5	NWezU2h1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInMNFhKSzVyPUKyMlk3KG6P	NFfy[\|hUSU6JRWK=
TGBC1TKB	NV;QVXFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnOyTWM2OD1{Mz6wOUBvVQ>?	NYrj[ldOW0GQR1XS
SW780	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jLOmlEPTB;MkOuNVMhdk1?	MYnTRW5ITVJ?
MG-63	MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPBfGdnUUN3ME2yN{41PSCwTR?=	NV3B[JBZW0GQR1XS
BV-173	MkDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVi0dYxUUUN3ME2yN{45PyCwTR?=	M2rkN3NCVkeHUh?=
CAL-51	MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTJ\|Lki5JI5O	NGfFR\|BUSU6JRWK=
A375	NWrMc4pZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXQPXRqUUN3ME2yN{46OyCwTR?=	NE\FU3JUSU6JRWK=
MEL-HO	NFHrO4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTJ2LkC0JI5O	NYnwT\|c2W0GQR1XS
EFO-27	NV7adlNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTJ2LkOzJI5O	Mke2V2FPT0WU
Hs-578-T	M4\wemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLPTHBjUUN3ME2yOE42QCCwTR?=	NIXwOnpUSU6JRWK=
NBsusSR	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGj0RZlKSzVyPUK0MlYhdk1?	MWHTRW5ITVJ?
CTB-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLWTWM2OD1{ND62O{BvVQ>?	M3PoR3NCVkeHUh?=
FTC-133	M1PB[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUn3bGdWUUN3ME2yOU4yKG6P	NVnqT3ZIW0GQR1XS
MOLT-4	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTJ3LkGyJI5O	M{\OO3NCVkeHUh?=
HO-1-N-1	NX:4SVl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoixTWM2OD1{NT6xOUBvVQ>?	M1X1bHNCVkeHUh?=
ES3	M3\0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULBdoxTUUN3ME2yOU4zOiCwTR?=	MljSV2FPT0WU
TI-73	Mlm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rU[WlEPTB;MkWuNlghdk1?	NES1enNUSU6JRWK=
MPP-89	M37rZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rS[mlEPTB;MkWuN\|Ihdk1?	NVrkd2t2W0GQR1XS
KYSE-150	MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVeySXI2UUN3ME2yOU45QSCwTR?=	NUi0S2ppW0GQR1XS
LXF-289	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DHOmlEPTB;Mk[uNFQhdk1?	M1\PTnNCVkeHUh?=
SK-LU-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfUTWM2OD1{Nj6xO{BvVQ>?	NFLVXZJUSU6JRWK=
HOP-92	MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTJ4LkS4JI5O	M{X5enNCVkeHUh?=
HuO9	M{T3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn23TWM2OD1{Nj63OkBvVQ>?	NYrJWmxHW0GQR1XS
SW962	NIPCOGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVz2RlBsUUN3ME2yOk44PiCwTR?=	MnTmV2FPT0WU
RS4-11	NHPSdppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoryTWM2OD1{Nj65NUBvVQ>?	M1HjRXNCVkeHUh?=
NCI-H292	M4\4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTJ5IH7N	MnG3V2FPT0WU
DB	MnjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTJ5LkO2JI5O	MkPCV2FPT0WU
SW1088	M4nzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYD4VnVqUUN3ME2yPE4zQSCwTR?=	NFPuRZhUSU6JRWK=
A204	NGTwNplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;3V2lEPTB;MkiuOFchdk1?	MUDTRW5ITVJ?
A3-KAW	NX;iR5lxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;nTWM2OD1{OD62OEBvVQ>?	NVPMd2ZGW0GQR1XS
MV-4-11	M2K4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF:4NHRKSzVyPUK4Mlchdk1?	NUnFPFl4W0GQR1XS
ES1	NUjJSYlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTJ6Lki0JI5O	NWG0bYtmW0GQR1XS
ONS-76	M3j2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;MeWlEPTB;MkmuNFUhdk1?	M3PjRnNCVkeHUh?=
D-263MG	NWHZZ\|Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTJ7LkO1JI5O	MVvTRW5ITVJ?
U-2-OS	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHL4XnRKSzVyPUK5MlUhdk1?	Mm\CV2FPT0WU
T98G	MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\pcWlEPTB;MkmuPFghdk1?	MnTlV2FPT0WU
GI-ME-N	M2LJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\yV2lEPTB;MkmuPVEhdk1?	NVzPS3hPW0GQR1XS
BHT-101	M{LtWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TpTWlEPTB;M{CuNFUhdk1?	MmHVV2FPT0WU
NOS-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTNyLkGyJI5O	MYfTRW5ITVJ?
AsPC-1	NH\RZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTNyLkKgcm0>	NEjsWm1USU6JRWK=
QIMR-WIL	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFe3NFlKSzVyPUOwMlYhdk1?	NX;vO\|Q3W0GQR1XS
JVM-3	NUH6WHpuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHtTWM2OD1\|MD64N{BvVQ>?	M3LFXXNCVkeHUh?=
KU-19-19	MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILhSFdKSzVyPUOxMlE{KG6P	M3HMPHNCVkeHUh?=
OVCAR-8	M{\hU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXr3VXlDUUN3ME2zNU4zPiCwTR?=	MnT1V2FPT0WU
BEN	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTNzLk[zJI5O	MlvPV2FPT0WU
BE-13	NETFNVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfvcngzUUN3ME2zNU45OiCwTR?=	NUTaUlZmW0GQR1XS
EW-18	M3XSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3THdmlEPTB;M{GuPFYhdk1?	MUHTRW5ITVJ?
ECC10	NYfxWoVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmi3TWM2OD1\|MT65OUBvVQ>?	MX3TRW5ITVJ?
CTV-1	M1PSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XkRWlEPTB;M{KuPFIhdk1?	NYPr[mtpW0GQR1XS
COLO-800	NF\FSoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWroe\|ZbUUN3ME2zNk46OiCwTR?=	M{DhZXNCVkeHUh?=
A2058	M1XyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFOzSlZKSzVyPUOzMlI2KG6P	MUPTRW5ITVJ?
VM-CUB-1	M1rSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHK0UpZKSzVyPUOzMlQ{KG6P	NUKxc\|djW0GQR1XS
Ca9-22	Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\xN21ZUUN3ME2zN{42PSCwTR?=	MoewV2FPT0WU
COLO-684	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDFfHREUUN3ME2zN{42QCCwTR?=	MVPTRW5ITVJ?
RPMI-8226	M4ThSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml20TWM2OD1\|Mz64NkBvVQ>?	NVu0TJlFW0GQR1XS
SK-NEP-1	NXfZNWc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrPTWM2OD1\|ND6xOUBvVQ>?	M4L2OHNCVkeHUh?=
Becker	NEnDeJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3LBVGlEPTB;M{SuNlEhdk1?	NXq2OZdqW0GQR1XS
NCI-H28	NVH0[Y5bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTN2LkS0JI5O	M37QUXNCVkeHUh?=
CAL-120	NVX6NWh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjRbnQ2UUN3ME2zOE44OiCwTR?=	NX7HT2lKW0GQR1XS
MDA-MB-157	Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDuTWM2OD1\|NT60NUBvVQ>?	MX3TRW5ITVJ?
OVCAR-5	MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTN3LkS3JI5O	MnjqV2FPT0WU
LAMA-84	NWG2dllCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3y1NGlEPTB;M{WuPFchdk1?	M{fDSnNCVkeHUh?=
CAKI-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfabVl5UUN3ME2zOk41OyCwTR?=	NXv4[olNW0GQR1XS
Daoy	M2m3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\SVGlEPTB;M{[uO{BvVQ>?	MoToV2FPT0WU
CAL-62	NXfQc45PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYWxSlA5UUN3ME2zOk45PiCwTR?=	NHv3[nVUSU6JRWK=
8-MG-BA	NWTRZZBUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTN5LkK1JI5O	MXjTRW5ITVJ?
8505C	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfKWGdKSzVyPUO3MlUyKG6P	M2\yRXNCVkeHUh?=
LNCaP-Clone-FGC	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\LeHlKSzVyPUO3MlU6KG6P	MnLIV2FPT0WU
CAL-39	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTN5Lkmgcm0>	M{XNUnNCVkeHUh?=
MN-60	NIOxcm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\STWM2OD1\|Nz65OkBvVQ>?	M1S5fnNCVkeHUh?=
RKO	M3jSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4P6R2lEPTB;M{iuN\|Mhdk1?	MoHNV2FPT0WU
U251	MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHKdoRsUUN3ME2zPE41OyCwTR?=	MYjTRW5ITVJ?
SJSA-1	NXzSTo1jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmG5TWM2OD1\|OD61OEBvVQ>?	M2n0NHNCVkeHUh?=
CAL-12T	NXrxXI5mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTN6Lk[gcm0>	NUHmdnVUW0GQR1XS
HCC1419	NIDjcYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFv4S\|RKSzVyPUO4MlcyKG6P	NHnLbnpUSU6JRWK=
CO-314	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XhT2lEPTB;M{iuO\|Qhdk1?	M1fXUHNCVkeHUh?=
LB1047-RCC	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXEVpRKSzVyPUO4MlgyKG6P	NXyxUYVtW0GQR1XS
A101D	Mk\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2n4WGlEPTB;M{iuPVchdk1?	MXvTRW5ITVJ?
MDA-MB-175-VII	M4rlRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTN7LkWxJI5O	MorLV2FPT0WU
MZ2-MEL	MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVf4dZdkUUN3ME2zPU43PiCwTR?=	M2Lh[nNCVkeHUh?=
NB5	NEDxcYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;abWlEPTB;NECuOlQhdk1?	MVfTRW5ITVJ?
G-401	NHPr[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\zWXBQUUN3ME20NE45OiCwTR?=	NYHqZ5lnW0GQR1XS
HT	NV;qZmxUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;sTWM2OD12MT6wNkBvVQ>?	NGLIZ\|lUSU6JRWK=
8305C	Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk[0TWM2OD12MT64O{BvVQ>?	NV70[plOW0GQR1XS
BHY	MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2P3bGlEPTB;NEKuO\|Ihdk1?	M{XzS3NCVkeHUh?=
NTERA-S-cl-D1	MomzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2[3eWlEPTB;NEOgcm0>	M1W3S3NCVkeHUh?=
T-24	NGHIbVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGLvcI9KSzVyPUSzMlg{KG6P	NHLlTYNUSU6JRWK=
EPLC-272H	NEn3bVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTR2LkO5JI5O	M4PMSHNCVkeHUh?=
PSN1	M2nVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvxWW9KSzVyPUS0MlQhdk1?	M4DUVHNCVkeHUh?=
NCI-H2452	NGrzO4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\hTWM2OD12ND61PEBvVQ>?	MYTTRW5ITVJ?
KS-1	NHnsR45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnyfJF4UUN3ME20OE43PiCwTR?=	MWXTRW5ITVJ?
HD-MY-Z	MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHyeYQ6UUN3ME20OE46OiCwTR?=	Mn20V2FPT0WU
KNS-62	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HZVWlEPTB;NEWuN\|ghdk1?	Ml75V2FPT0WU
NOMO-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{i1SWlEPTB;NEWuPFchdk1?	MmSzV2FPT0WU
SK-HEP-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\HTWM2OD12Nj6wOEBvVQ>?	M{DJZ3NCVkeHUh?=
IGR-1	NWqxSlNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2n4c2lEPTB;NE[uNVMhdk1?	MXnTRW5ITVJ?
KYSE-180	NHPhdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M373O2lEPTB;NE[uNVchdk1?	MmS4V2FPT0WU
EW-22	NXXV[YZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3OTWM2OD12Nj6yJI5O	MVXTRW5ITVJ?
NCI-H1355	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTR4LkO0JI5O	M4XYNHNCVkeHUh?=
DOHH-2	NUL0bnRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHjTWM2OD12Nj6zO{BvVQ>?	MorXV2FPT0WU
A4-Fuk	MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnBO2pwUUN3ME20Ok42OiCwTR?=	MkHUV2FPT0WU
PC-14	NXfGUmJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTR4LkW3JI5O	MWDTRW5ITVJ?
TE-5	NFzYZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHv1SmJKSzVyPUS2Mlg1KG6P	MkDPV2FPT0WU
LB996-RCC	Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTR5LkG5JI5O	NGXvXnpUSU6JRWK=
NCI-H1623	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofVTWM2OD12Nz63OkBvVQ>?	NWfqWmtQW0GQR1XS
NCI-H1155	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnYTXBKSzVyPUS4MlMzKG6P	MWLTRW5ITVJ?
LoVo	MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nhe2lEPTB;NEiuOEBvVQ>?	M{nYW3NCVkeHUh?=
MCF7	NFPKNGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXwRohsUUN3ME20PE42QCCwTR?=	NYX3[lZJW0GQR1XS
AGS	NIfvd4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIr4UIJKSzVyPUS4Mlc4KG6P	NI\PdnVUSU6JRWK=
PFSK-1	NXjGVHJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmf0TWM2OD12OT6wOkBvVQ>?	MoD2V2FPT0WU
22RV1	MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fVbGlEPTB;NEmuNFkhdk1?	NGDq[2dUSU6JRWK=
COR-L23	NWPT[WRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7oTWM2OD12OT6xOkBvVQ>?	M4q2UHNCVkeHUh?=
D-283MED	M2S0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTR7Lk[xJI5O	NX7m[3d4W0GQR1XS
SW982	NF;wbW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jmRmlEPTB;NEmuPVEhdk1?	NF7je5lUSU6JRWK=
SW620	NX6xO401T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTVyLkO2JI5O	MUnTRW5ITVJ?
KYSE-140	NF\JdHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTVyLkW1JI5O	MmjyV2FPT0WU
GCIY	NGXBN3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLRb5JKSzVyPUWwMlY4KG6P	NV;pNHQzW0GQR1XS
MHH-ESS-1	NY[y[IlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzxUIZKSzVyPUWxMlk2KG6P	MVzTRW5ITVJ?
D-423MG	NUDoS2tzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmSwTWM2OD13Mj6wPEBvVQ>?	NIXZRXNUSU6JRWK=
SF539	MoDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTkTWM2OD13Mj6zOUBvVQ>?	MVPTRW5ITVJ?
RPMI-2650	NEnjfZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHH0OlhKSzVyPUWyMlY6KG6P	MV;TRW5ITVJ?
GR-ST	Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjufplKSzVyPUWyMlg4KG6P	MULTRW5ITVJ?
YKG-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;6cpBKSzVyPUWzJI5O	NHLMNFNUSU6JRWK=
SK-MES-1	M4jEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XieGlEPTB;NUOuNlYhdk1?	NV7WcYZmW0GQR1XS
HLE	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTV\|LkS3JI5O	Mn[zV2FPT0WU
RVH-421	NEfB[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{T5fGlEPTB;NUOuOlchdk1?	NUD0dIRDW0GQR1XS
C32	M2LXRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TKNmlEPTB;NUOuPFMhdk1?	MoH3V2FPT0WU
GB-1	NHrRWYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTV2LkKgcm0>	M1jKRXNCVkeHUh?=
SNB75	MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\qTWM2OD13ND6yOkBvVQ>?	NVf3T3hXW0GQR1XS
EM-2	M4Hvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPoOG5[UUN3ME21OE41KG6P	NV:1PVhSW0GQR1XS
RH-1	NHnieHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnCTWM2OD13ND63JI5O	NUfMfFhXW0GQR1XS
NKM-1	MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrn[YFsUUN3ME21OE45OSCwTR?=	M4Xnd3NCVkeHUh?=
NCI-H2405	MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTV2Lki4JI5O	NWD1clBSW0GQR1XS
KYSE-450	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Moq4TWM2OD13NT6xOkBvVQ>?	M4jKU3NCVkeHUh?=
A704	M4\ZSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfhZoxPUUN3ME21OU42QSCwTR?=	MYnTRW5ITVJ?
HAL-01	NUXxWVlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPrTWM2OD13NT64N{BvVQ>?	Ml65V2FPT0WU
TE-11	M3iyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXnDOldTUUN3ME21OU46QSCwTR?=	NUfzVFdDW0GQR1XS
DOK	NXrkVYE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDJZZVNUUN3ME21Ok4xOiCwTR?=	MmP5V2FPT0WU
KY821	NYnVc4ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2D2O2lEPTB;NU[uNkBvVQ>?	NVrnPWVHW0GQR1XS
KGN	M2nzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPLTWM2OD13Nj6zNkBvVQ>?	NVHIb3dyW0GQR1XS
MC116	M3uyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrpTWM2OD13Nz64JI5O	M3rsWnNCVkeHUh?=
PANC-08-13	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPMboxuUUN3ME21PE4xOSCwTR?=	NFn0UG5USU6JRWK=
KE-37	MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfLRoE{UUN3ME21PE44PyCwTR?=	NVLYW25XW0GQR1XS
KYSE-410	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\pTJJKSzVyPUW5MlQ4KG6P	MnG2V2FPT0WU
RO82-W-1	MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXjTWM2OD13OT65JI5O	NV;mRZlkW0GQR1XS
M14	NYrUZ5l2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TtPWlEPTB;NkCuNFQhdk1?	MULTRW5ITVJ?
GI-1	NF;5RZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfvNHdxUUN3ME22NE4{KG6P	NEPRdXRUSU6JRWK=
ML-2	NHjMNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mof6TWM2OD14MD62NkBvVQ>?	NIfCXlhUSU6JRWK=
BFTC-905	M17pVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrSOIp[UUN3ME22NE43PSCwTR?=	M2PVOXNCVkeHUh?=
DMS-273	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HYXWlEPTB;NkCuPFchdk1?	M2rp[nNCVkeHUh?=
MDA-MB-361	M17M[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfSTWM2OD14MTDuUS=>	MlfPV2FPT0WU
MSTO-211H	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXSxS4F6UUN3ME22N{42OSCwTR?=	MoPzV2FPT0WU
MEG-01	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLaXoFLUUN3ME22N{42OiCwTR?=	NX;ve5JIW0GQR1XS
M059J	MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXhXZVKSzVyPU[zMlU5KG6P	M2nlV3NCVkeHUh?=
LN-405	NWOzb3FmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPGdVR2UUN3ME22N{45PSCwTR?=	NYn2eFduW0GQR1XS
NCI-H1581	NFvSVXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PHS2lEPTB;NkSuNFMhdk1?	NVXFNIs2W0GQR1XS
TCCSUP	M4rDZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fZOWlEPTB;NkSuOVMhdk1?	NV;Ke5RLW0GQR1XS
SW872	M2riXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M12x[WlEPTB;NkSuOVchdk1?	Mn7yV2FPT0WU
KYSE-510	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTZ3Lke1JI5O	Mlu0V2FPT0WU
NCI-H1792	NFPpVXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fYN2lEPTB;Nk[uNVUhdk1?	NHzGPHRUSU6JRWK=
SW13	NYT6ZpNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTZ4LkWgcm0>	M2XvVHNCVkeHUh?=
TE-8	NVzYSZA5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTZ4LkWyJI5O	NYGzTmhrW0GQR1XS
SCH	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUn6fnp7UUN3ME22O{4yKG6P	MVXTRW5ITVJ?
NEC8	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTsTWM2OD14Nz6yOEBvVQ>?	M{XWWXNCVkeHUh?=
HuO-3N1	NHr0ZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLYXFkzUUN3ME22O{4{OSCwTR?=	NV\0Tnp5W0GQR1XS
EFM-19	NVvT[\|V[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTNeodLUUN3ME22O{42KG6P	MofZV2FPT0WU
HEC-1	NUHkT4RPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37ZWWlEPTB;NkeuOVIhdk1?	NIXaZnlUSU6JRWK=
T47D	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXOPYdKSzVyPU[3Mlg4KG6P	M{\SXXNCVkeHUh?=
SNU-423	NXXBXZNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWmweJZqUUN3ME22O{46QCCwTR?=	NVG0OWhiW0GQR1XS
WM-115	NUfEb4NOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrBT4x{UUN3ME22PE4yPCCwTR?=	MknwV2FPT0WU
CaR-1	MmnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrsU\|BOUUN3ME22PE4zPSCwTR?=	Mle5V2FPT0WU
KU812	M1zjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTZ6Lk[5JI5O	NGj3NFlUSU6JRWK=
AM-38	NX3KbZpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;VO2lEPTB;NkmuN\|Ehdk1?	NWjQfpk3W0GQR1XS
KOSC-2	NXLh[3p4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXqe3J5UUN3ME22PU46PyCwTR?=	MVvTRW5ITVJ?
MC-IXC	M3fXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEiwVZdKSzVyPUewMlA5KG6P	M1;6NnNCVkeHUh?=
SCC-4	NE\ETYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjmfZhKSzVyPUexMlM5KG6P	MWfTRW5ITVJ?
Calu-3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXu3eWV3UUN3ME23NU46QCCwTR?=	M3y1cXNCVkeHUh?=
RPMI-8866	NIfJSJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\4ZmlKSzVyPUeyMlgzKG6P	M4LFZXNCVkeHUh?=
OVCAR-4	NX\z[XBoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\oe3RlUUN3ME23N{4{PiCwTR?=	MXnTRW5ITVJ?
OAW-42	NYTV[W1xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnTUFBjUUN3ME23N{4{QSCwTR?=	MofCV2FPT0WU
ATN-1	M3XYNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17LTGlEPTB;N{OuPFchdk1?	M{nU[HNCVkeHUh?=
CHP-212	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTd2Lkm1JI5O	NID2S2NUSU6JRWK=
C2BBe1	M{K4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PQO2lEPTB;N{WuNFMhdk1?	MYrTRW5ITVJ?
A498	NYTIeZU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHHZpJQUUN3ME23OU4yPSCwTR?=	NE\WfnhUSU6JRWK=
SH-4	NWrBd40zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXRUmFoUUN3ME23OU4zOSCwTR?=	NF;mSGpUSU6JRWK=
SNU-449	NYDtRVNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvWTWM2OD15NT63PUBvVQ>?	NHK4NGFUSU6JRWK=
RD	M1joSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{Xn[GlEPTB;N{WuPFYhdk1?	MnrFV2FPT0WU
PANC-03-27	MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTd4LkK1JI5O	NWfsXHljW0GQR1XS
S-117	M1:x[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTd4LkK3JI5O	M2f1TXNCVkeHUh?=
SK-MEL-2	Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTd4Lke1JI5O	MYTTRW5ITVJ?
LK-2	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV61bHJrUUN3ME23O{4xPSCwTR?=	MmPJV2FPT0WU
CP50-MEL-B	NWHNWWFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUD2S4NjUUN3ME23O{41KG6P	MX7TRW5ITVJ?
647-V	M2XEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFq0O3NKSzVyPUe4MlA4KG6P	MU\TRW5ITVJ?
LU-134-A	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fyOmlEPTB;N{muNFMhdk1?	MlTVV2FPT0WU
5637	Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3P5VWlEPTB;N{muNlMhdk1?	NWDq[JNPW0GQR1XS
NCI-H1437	MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRThyLkWgcm0>	M1;xUHNCVkeHUh?=
NCI-H460	NXXsb\|VwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRThzLkKzJI5O	NXXxPWdLW0GQR1XS
BxPC-3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTqW5J3UUN3ME24NU41PiCwTR?=	NH7sOJlUSU6JRWK=
CAN	NVXzeJgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLwPVJKSzVyPUixMlg1KG6P	Mnr4V2FPT0WU
KINGS-1	M330e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mkm1TWM2OD16Mj6zNkBvVQ>?	M2rDbnNCVkeHUh?=
OCUB-M	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWntRoFoUUN3ME24Nk41OSCwTR?=	NV;T[phUW0GQR1XS
KALS-1	M2TPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTh{LkW0JI5O	MUnTRW5ITVJ?
OCI-AML2	NHq4UZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;oR3U3UUN3ME24Nk43OSCwTR?=	Mn\6V2FPT0WU
A253	NILuWGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rLUWlEPTB;OEKuOlUhdk1?	MoHEV2FPT0WU
LCLC-97TM1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3SXHIzUUN3ME24Nk45PiCwTR?=	MkC1V2FPT0WU
NCI-H520	M4jWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XhNmlEPTB;OEOuNFYhdk1?	NHPmbo5USU6JRWK=
P30-OHK	NGnrTWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX:3ZoM1UUN3ME24N{42KG6P	MknvV2FPT0WU
SBC-5	M2rac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXP6c4dOUUN3ME24N{42OiCwTR?=	NVr3SGRjW0GQR1XS
HCE-T	M1SybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2Po[2lEPTB;OEOuO\|Qhdk1?	MWDTRW5ITVJ?
JEG-3	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTh2LkGgcm0>	NUHWe5FwW0GQR1XS
KG-1	NV;u[IF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{CwTGlEPTB;OESuNlQhdk1?	Mk\HV2FPT0WU
MIA-PaCa-2	NVvlS4JyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTh2LkW0JI5O	NH3qe3pUSU6JRWK=
CAL-33	NHnaOmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTh3LkC4JI5O	M3TyOnNCVkeHUh?=
639-V	M4\5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlT5TWM2OD16NT60NkBvVQ>?	MkLIV2FPT0WU
NCI-H1048	MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXsOGpKSzVyPUi2MlMyKG6P	M2\NOnNCVkeHUh?=
NCI-H1573	NFnIOnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofLTWM2OD16Nz60PEBvVQ>?	MXzTRW5ITVJ?
NCI-H2228	MmfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTh6LkK2JI5O	NYrUSIlEW0GQR1XS
NB14	Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWSzT25bUUN3ME24PE4{KG6P	MoP1V2FPT0WU
SCC-25	M3;EU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXJSHptUUN3ME24PU45OiCwTR?=	NUDFZ4F4W0GQR1XS
A431	NX\qR5c2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnnTWM2OD16OT65O{BvVQ>?	M1[3V3NCVkeHUh?=
SN12C	MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTlyLk[yJI5O	NYDCRXh1W0GQR1XS
HuCCT1	NGfkVJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfSVpFKSzVyPUmwMlc3KG6P	M2PsfnNCVkeHUh?=
LS-123	NXSzbVdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjaTWM2OD17Mj6xPEBvVQ>?	NV74eXREW0GQR1XS
CAL-85-1	MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\5VGlEPTB;OUKuOFghdk1?	NGDQOVRUSU6JRWK=
ES6	M2iyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTl{LkizJI5O	M2G0R3NCVkeHUh?=
NCI-H650	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFO5ZmdKSzVyPUm0MlA6KG6P	NHq4W\|FUSU6JRWK=
NCI-H446	NFvNZ\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTl3LkGyJI5O	MVHTRW5ITVJ?
EW-13	MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LubmlEPTB;OUWuO\|Uhdk1?	NX\WU5c5W0GQR1XS
HSC-2	NUTJNYJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4e4c2lEPTB;OUWuPFkhdk1?	NGjXRWNUSU6JRWK=
U031	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33qc2lEPTB;OU[uO\|Mhdk1?	M2jjc3NCVkeHUh?=
EW-11	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7oTWM2OD17Nj64PEBvVQ>?	Ml;hV2FPT0WU
GAK	MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPsTWM2OD17OD65N{BvVQ>?	M{XCbHNCVkeHUh?=
SK-OV-3	M3HJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvtZZdKSzVyPUGwNE4xPyCwTR?=	MYPTRW5ITVJ?
OMC-1	M1HKbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3naRWlEPTB;MUCwMlE5KG6P	M{K0TnNCVkeHUh?=
TK10	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\xSYdKSzVyPUGwNE4zOSCwTR?=	NWLw[WNyW0GQR1XS
EKVX	MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULHPFBtUUN3ME2xNFAvPiCwTR?=	NIG5TVFUSU6JRWK=
Detroit562	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37HSGlEPTB;MUCyMlE4KG6P	NIfn[GxUSU6JRWK=
SF268	M4PUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;EemlEPTB;MUCyMlM1KG6P	MUXTRW5ITVJ?
SNU-387	MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU[3SlJGUUN3ME2xNFQvOTdibl2=	NXTxOY5HW0GQR1XS
MDA-MB-231	M4jyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvRTWM2OD1zMEWuNFYhdk1?	Ml;NV2FPT0WU
NCI-H1563	MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXsTWM2OD1zMEWuNVghdk1?	M2q4TnNCVkeHUh?=
D-502MG	NGjY[YVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTFyNT63JI5O	MX;TRW5ITVJ?
A2780	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXVTWM2OD1zME[uOFchdk1?	NGS2VoxUSU6JRWK=
IA-LM	NYTD[HFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX:5[W41UUN3ME2xNFcvPTFibl2=	NXjV[WVoW0GQR1XS
D-392MG	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TJ[GlEPTB;MUC3MlU1KG6P	MnK2V2FPT0WU
MS-1	NUTh[mo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTFyNz63NUBvVQ>?	NHn0cYZUSU6JRWK=
SW1990	M4XncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrO[HFKSzVyPUGwPE42PCCwTR?=	NXPIdlh[W0GQR1XS
HEL	NWPnOWd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmm1TWM2OD1zMEmuNlkhdk1?	M3vSenNCVkeHUh?=
SW1573	Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LpV2lEPTB;MUC5MlMyKG6P	M{XzUnNCVkeHUh?=
SW1783	NGWxN4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TkSGlEPTB;MUGwMlIzKG6P	MYPTRW5ITVJ?
COLO-680N	NI\LXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnVTWM2OD1zMUCuO\|Yhdk1?	MVPTRW5ITVJ?
NCI-N87	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;4VmlKSzVyPUGxNU4xPCCwTR?=	M1;UWXNCVkeHUh?=
SK-MEL-28	MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTFzMT61OUBvVQ>?	NX;5boN1W0GQR1XS
BT-20	NF;rVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTFzMj6wNUBvVQ>?	MnXxV2FPT0WU
NCI-H1648	NY\RfoY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknCTWM2OD1zMUOgcm0>	NFX2epNUSU6JRWK=
no-11	MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX:0NphVUUN3ME2xNVMvOjhibl2=	NULU[4Z3W0GQR1XS
MOLT-13	NIDWTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTFzMz60OEBvVQ>?	NEOzeodUSU6JRWK=
NCI-H2170	NEC1dphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\DTWM2OD1zMUSuOVEhdk1?	MnrxV2FPT0WU
HTC-C3	M1XYVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUCwT\|FQUUN3ME2xNVYvQDVibl2=	MUHTRW5ITVJ?
LU-99A	NH72XpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\2TWM2OD1zMUeuNlEhdk1?	NIKyZnZUSU6JRWK=
HCC2998	NUXpXWxuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmH5TWM2OD1zMUeuPVIhdk1?	Mo\PV2FPT0WU
NB13	Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLtTWM2OD1zMUeuPVkhdk1?	NXm4ZplwW0GQR1XS
GT3TKB	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTFzOD6wPEBvVQ>?	MWTTRW5ITVJ?
BT-549	M{T6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\4TWM2OD1zMUiuPVUhdk1?	NULXVHBWW0GQR1XS
NCI-H747	NYjrVJE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TZR2lEPTB;MUG5MlM1KG6P	MoH6V2FPT0WU
EW-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mkf6TWM2OD1zMkCuNkBvVQ>?	NYnzN5JDW0GQR1XS
LB831-BLC	NIDVfYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTsTWM2OD1zMkCuOlMhdk1?	MnvGV2FPT0WU
NMC-G1	Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mon2TWM2OD1zMkGuNVEhdk1?	MkTKV2FPT0WU
COLO-679	NUHjNmI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLVZXpKSzVyPUGyNk4yPSCwTR?=	MmW3V2FPT0WU
HL-60	M1q3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUXZbVZKUUN3ME2xNlMvOSCwTR?=	NIrCO\|dUSU6JRWK=
MKN7	NVjjNIJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYT5PG1lUUN3ME2xNlMvQDNibl2=	NWHTXot7W0GQR1XS
RERF-LC-MS	M1PWVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTnTWM2OD1zMkSuN\|Ehdk1?	NHLobJJUSU6JRWK=
DMS-114	NWqyUJVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorJTWM2OD1zMkWuNFkhdk1?	Mn\sV2FPT0WU
HuP-T4	NYLq[4tLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXS5[HJHUUN3ME2xNlYvQTdibl2=	NGrtbVlUSU6JRWK=
HCC2157	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTF{Nz61JI5O	M3PvUHNCVkeHUh?=
SKG-IIIa	NGSxWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPCTWM2OD1zMkiuPEBvVQ>?	MnK4V2FPT0WU
HCT-116	NYPremZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTlS4YzUUN3ME2xN\|AvPjRibl2=	NHK2bolUSU6JRWK=
BB30-HNC	MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTF\|MD63PEBvVQ>?	MV3TRW5ITVJ?
KYSE-270	NVPPfnY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTBRVhSUUN3ME2xN\|AvQDhibl2=	MYfTRW5ITVJ?
MFM-223	Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfWTWM2OD1zM{GuOVEhdk1?	MUHTRW5ITVJ?
NH-12	NWDFc2xzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3j2UWlEPTB;MUOyMlk6KG6P	M3LvVXNCVkeHUh?=
U-118-MG	M4fD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGGzV2pKSzVyPUGzN{43OiCwTR?=	MXjTRW5ITVJ?
ESS-1	M1LKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlWwTWM2OD1zM{WuNVghdk1?	NInS[nFUSU6JRWK=
D-247MG	NG\kZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTF\|NT6yNUBvVQ>?	MkD5V2FPT0WU
IGROV-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XkVWlEPTB;MUO1Mlc3KG6P	NVmwVnJnW0GQR1XS
C-33-A	NETXbJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPRWZBKSzVyPUGzOU46PyCwTR?=	M3\DN3NCVkeHUh?=
NCI-H1693	M3;LR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XYXmlEPTB;MUO2MlEzKG6P	MXLTRW5ITVJ?
MLMA	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HGdWlEPTB;MUO2MlU5KG6P	M4S2O3NCVkeHUh?=
SK-N-AS	M1jON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUO4PHlyUUN3ME2xN\|cvOTdibl2=	MlrNV2FPT0WU
NCI-H1755	MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTF\|OD64OUBvVQ>?	M1XkfHNCVkeHUh?=
CHP-134	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPUT\|RvUUN3ME2xN\|kvPTVibl2=	NILXSo9USU6JRWK=
LS-513	M4HoTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mom0TWM2OD1zNECuPVEheE1?	NVK5No1kW0GQR1XS
TE-12	NYL1NpI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTF2MD65N{BvVQ>?	NVzxNWFkW0GQR1XS
KNS-42	NWDhdHV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFL5cHVKSzVyPUG0OE4{KG6P	NYrzOZZyW0GQR1XS
SJRH30	NF22OXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTF2ND60OEBvVQ>?	MV;TRW5ITVJ?
NCI-H1092	NWXPXm17T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTF2ND61NkBvVQ>?	NF\wOW9USU6JRWK=
H-EMC-SS	M3\PcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTF2Nj64NUBvVQ>?	NYHQW3I3W0GQR1XS
SK-MEL-3	MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVW5e5VEUUN3ME2xOFcvPTVibl2=	M3\VOnNCVkeHUh?=
SK-N-FI	M4TsOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjFTWM2OD1zNEeuOVkhdk1?	NV\nZ5F6W0GQR1XS
NCI-H2126	M13jbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DmRWlEPTB;MUS4MlE2KG6P	MU\TRW5ITVJ?
NCI-H1299	M{XCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTF3MD6yNkBvVQ>?	NI\UfXNUSU6JRWK=
CFPAC-1	MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\UTGZKSzVyPUG1NE43PiCwTR?=	MmXnV2FPT0WU
NCI-H661	NWTxdIx1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1uyUGlEPTB;MUWxMlI3KG6P	MlTOV2FPT0WU
KYSE-70	NHLU[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\QV5NKUUN3ME2xOVEvPzlibl2=	NHTFOlJUSU6JRWK=
SW900	M3vROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTF3ND62OUBvVQ>?	NGqxZotUSU6JRWK=
Ca-Ski	M1jTfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTF3Nj6zPUBvVQ>?	Mli3V2FPT0WU
HPAF-II	NEfYSJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTF3Nj60O{BvVQ>?	NXrNN2tWW0GQR1XS
LB2518-MEL	M12wWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTF3Nz6xJI5O	MV\TRW5ITVJ?
LC-2-ad	MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrTU2o2UUN3ME2xOVgvPjJibl2=	MkPNV2FPT0WU
HCC1806	M2TBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTxTWM2OD1zNkeuPFghdk1?	MoK1V2FPT0WU
UACC-62	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4H6d2lEPTB;MU[4MlA6KG6P	MWLTRW5ITVJ?
KM-H2	M2HFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTF5MD61PEBvVQ>?	NWfpOG9KW0GQR1XS
NCI-H2347	NEHEfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;xWmlEPTB;MUeyMlczKG6P	NVLLVlVRW0GQR1XS
SCC-15	MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DWbGlEPTB;MUezMlY3KG6P	Mn33V2FPT0WU
BB49-HNC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnP1TWM2OD1zN{OuPFEhdk1?	NHLtRYpUSU6JRWK=
GMS-10	NVq1S2VuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULMUXhoUUN3ME2xO\|MvQTRibl2=	NIfPR2RUSU6JRWK=
NCI-H2052	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fIV2lEPTB;MUe0Mlkhdk1?	Ml\wV2FPT0WU
SW626	MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHJTWM2OD1zN{[uNFYhdk1?	NGG5bWNUSU6JRWK=
MDA-MB-415	NELUXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULmU5ozUUN3ME2xO\|YvPjFibl2=	M{PKPHNCVkeHUh?=
Saos-2	Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWq5XHg2UUN3ME2xO\|kvOzVibl2=	MUnTRW5ITVJ?
DK-MG	Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTF6MD6zJI5O	MVHTRW5ITVJ?
SNU-C2B	NVHkelhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTF6MD63N{BvVQ>?	M3W4WnNCVkeHUh?=
A427	MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHzTWM2OD1zOEKuOVchdk1?	MYnTRW5ITVJ?
KP-N-YS	NInJZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13rT2lEPTB;MUi1JI5O	NFjOPJhUSU6JRWK=
J82	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFPrcZZKSzVyPUG4OU4yQCCwTR?=	MXnTRW5ITVJ?
LS-411N	Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTF6Nz6yPEBvVQ>?	MYHTRW5ITVJ?
HCC1937	NWC3eXQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInRbFRKSzVyPUG4O{41QSCwTR?=	NXHyT3JNW0GQR1XS
OE33	MonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWH2PXNEUUN3ME2xPFgvQTdibl2=	NXm0cnhIW0GQR1XS
NB7	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTF6OT64PUBvVQ>?	NFuwU\|NUSU6JRWK=
SW684	NGf5e3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\U[2lEPTB;MUm2MlE{KG6P	MWfTRW5ITVJ?
HT-144	NXPJ[ZFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX2yXYNrUUN3ME2xPVYvOTVibl2=	MUPTRW5ITVJ?
SK-MEL-30	NITqVGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETIdWpKSzVyPUG5Ok4zKG6P	MULTRW5ITVJ?
DBTRG-05MG	NFTaXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PlfWlEPTB;MUm4MlQ4KG6P	NF\RSpJUSU6JRWK=
NCI-H1395	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEj2eFZKSzVyPUG5PE45PSCwTR?=	M3\XbHNCVkeHUh?=
NCI-H2122	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULY[\|k5UUN3ME2yNFAvPTlibl2=	NFKzbodUSU6JRWK=
no-10	NV31NlloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rPXGlEPTB;MkCxMlA1KG6P	MmHYV2FPT0WU
SW48	M3jXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XaNWlEPTB;MkCxMlMyKG6P	NIjjd4xUSU6JRWK=
NCI-H1650	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnuTZdKSzVyPUKwOE4xOSCwTR?=	MnPHV2FPT0WU
MZ1-PC	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTJyNT61PEBvVQ>?	MmrSV2FPT0WU
U-266	Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1eyd2lEPTB;MkC1Mlc6KG6P	M13MSXNCVkeHUh?=
CAS-1	Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fxOWlEPTB;MkC3MlQ1KG6P	MXrTRW5ITVJ?
AU565	NIPEW29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Moi4TWM2OD1{MUKuPFIhdk1?	M1G1W3NCVkeHUh?=
UACC-257	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTQTWM2OD1{MUOuPVkhdk1?	MnS0V2FPT0WU
CAL-27	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHYSJhKSzVyPUKxO{4xPSCwTR?=	NVLwe5JYW0GQR1XS
NCI-H23	NUnW[oxyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULPdmVbUUN3ME2yNVkvOzNibl2=	MYPTRW5ITVJ?
TE-6	M3;WWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTJzOT62PEBvVQ>?	NV[4emtpW0GQR1XS
TGBC24TKB	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXmSZhKSzVyPUKyNk4yPyCwTR?=	NGHObmRUSU6JRWK=
TE-1	M3\oW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;CUmlEPTB;MkKyMlg5KG6P	MmrxV2FPT0WU
RCC10RGB	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;GTWM2OD1{MkSuNVkhdk1?	MV\TRW5ITVJ?
NCI-H596	NWKwVnJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfr[I1KSzVyPUKyPE4zOiCwTR?=	M16w[3NCVkeHUh?=
SW954	NW\IOYRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrRTWM2OD1{M{OuPFMhdk1?	NUXxb5ViW0GQR1XS
NCI-H2087	M1TEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDxTWM2OD1{M{SuOVEhdk1?	MonyV2FPT0WU
SK-PN-DW	NHzXWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTJ\|NT6xPUBvVQ>?	M2flTXNCVkeHUh?=
KM12	M{fjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF60WJNKSzVyPUKzOU44KG6P	NX\me\|A1W0GQR1XS
BT-474	NFT1O2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTJ\|NT63N{BvVQ>?	MlTSV2FPT0WU
IST-MES1	NHLKZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTJ\|Nj61O{BvVQ>?	MVnTRW5ITVJ?
HT-1197	M13IPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTJ\|OD6wPUBvVQ>?	MYnTRW5ITVJ?
CAL-54	NX3xS44yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTJ\|OD60PUBvVQ>?	NIS3R41USU6JRWK=
NB10	MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITSepRKSzVyPUK0NE4xPiCwTR?=	M4HHTHNCVkeHUh?=
PANC-10-05	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYiyTHhiUUN3ME2yOFUvPTZibl2=	NF;DUJlUSU6JRWK=
NCI-H522	NXr1b\|NsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;KR5lKSzVyPUK0PE4{OSCwTR?=	M3HaVnNCVkeHUh?=
A388	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jE[GlEPTB;MkS5MlgzKG6P	MlLyV2FPT0WU
GOTO	MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;vN5RKSzVyPUK1NE4zQSCwTR?=	NULMZVA5W0GQR1XS
KLE	MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHHU2xKUUN3ME2yOVEvQDdibl2=	NFvzZ2tUSU6JRWK=
KYSE-520	NV\Xcm4xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPOTWM2OD1{NUKuPFYhdk1?	NGTVSmlUSU6JRWK=
HCE-4	NU\RT4tpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInYWZdKSzVyPUK2Nk42KG6P	NUnJZ3R[W0GQR1XS
KURAMOCHI	NGnieVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPDS\|JqUUN3ME2yOlUvQSCwTR?=	MYfTRW5ITVJ?
HCC38	M3LQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmWyTWM2OD1{Nk[uOFghdk1?	NYmxTWtRW0GQR1XS
FADU	NUS1O\|BTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTJ4Nj62N{BvVQ>?	MoiyV2FPT0WU
CW-2	NGjxd\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TsWWlEPTB;Mk[5Mlk3KG6P	NYjKTo86W0GQR1XS
L-428	NYnZeJpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPlSWJrUUN3ME2yO\|UvOTVibl2=	MonHV2FPT0WU
HCC1569	M4XMOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrCTWM2OD1{N{WuPFQhdk1?	NXvDUpNDW0GQR1XS
NCI-H810	NH3iRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTJ5OD6zNUBvVQ>?	NVTmbWZvW0GQR1XS
LB771-HNC	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnqTpl3UUN3ME2yPFUvQDRibl2=	M1TZS3NCVkeHUh?=
LCLC-103H	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfhb2hKSzVyPUK4OU46QSCwTR?=	M4n6TXNCVkeHUh?=
EFO-21	M1rtOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHf5eIxKSzVyPUK4O{43QCCwTR?=	NEHKUoxUSU6JRWK=
CAL-72	M4HiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nZOWlEPTB;MkmzMlE6KG6P	NHPaPG1USU6JRWK=
SCC-9	MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF2wbVRKSzVyPUK5N{4zOiCwTR?=	NXzQWGVyW0GQR1XS
COLO-829	NF74fI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3y0WGlEPTB;Mkm2MlUhdk1?	NF;I[otUSU6JRWK=
U-87-MG	NFfUSVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTNyMD63N{BvVQ>?	MYTTRW5ITVJ?
MZ7-mel	M2TzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPaO29KSzVyPUOyN{44PiCwTR?=	MWnTRW5ITVJ?
NCI-H1770	MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4naVWlEPTB;M{K2Mlc1KG6P	MXnTRW5ITVJ?
ChaGo-K-1	M1H2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3O1[mlEPTB;M{K4MlEhdk1?	M3HyVXNCVkeHUh?=
SiHa	NVfmN5dYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTN{OT6yOEBvVQ>?	MknVV2FPT0WU
NCI-SNU-5	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTN\|Nj63O{BvVQ>?	MVTTRW5ITVJ?
DJM-1	M3WwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTN2MD6zN{BvVQ>?	MoHNV2FPT0WU
OE19	NEPnWmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTN2MD61N{BvVQ>?	NGrWeXRUSU6JRWK=
NCI-H1651	NI\6c4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGC0ZoFKSzVyPUO0OE4yQCCwTR?=	NHzEbWNUSU6JRWK=
COLO-792	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nRZWlEPTB;M{W0MlQzKG6P	M1\YN3NCVkeHUh?=
ACHN	NX;ZT25NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjJe5JKSzVyPUO1Ok44OSCwTR?=	Moj5V2FPT0WU
TH-3	M{nvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTN5OT65OUBvVQ>?	MXLTRW5ITVJ?
HT-1376	NVTD[253T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTN6ND64PEBvVQ>?	M4PSU3NCVkeHUh?=
RH-18	M1vheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmq5TWM2OD1\|OUSuO\|Qhdk1?	MnjXV2FPT0WU
NB6	NYLHPZBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTN7Nj62OkBvVQ>?	MmPPV2FPT0WU
COLO-320-HSR	MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTke\|FUUUN3ME20NFMvOzdibl2=	M3jrRXNCVkeHUh?=
UACC-893	MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPtTWM2OD12ME[uOFchdk1?	NEnqNmxUSU6JRWK=
DSH1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHDWZFKSzVyPUSwOk46OSCwTR?=	NVPWNop{W0GQR1XS
TE-10	NVXk[\|kzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljWTWM2OD12MEeuNFEhdk1?	M4i5NXNCVkeHUh?=
HCC70	NUCz[HFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTRyOT6yNUBvVQ>?	M2nPOHNCVkeHUh?=
TGBC11TKB	Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTRzMD6zN{BvVQ>?	NFjYRVlUSU6JRWK=
NCI-H727	NV7QbYxpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXX0bnpWUUN3ME20NVIvOTFibl2=	M364NXNCVkeHUh?=
ALL-PO	M4PTb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjsXIZKSzVyPUSxOU43QSCwTR?=	NITiZo1USU6JRWK=
ABC-1	NEjr[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDxTWM2OD12MkCuOFUhdk1?	MV;TRW5ITVJ?
NCI-H69	MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXS4[W82UUN3ME20NlYvPzZibl2=	NFzlT\|JUSU6JRWK=
GP5d	NIfWZ4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTvTWM2OD12M{SuOFEhdk1?	M2[3NHNCVkeHUh?=
UMC-11	NWXr[oZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{n0O2lEPTB;NEW4MlM3KG6P	MlnKV2FPT0WU
RMG-I	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTR4Nz61OkBvVQ>?	NUPNcWNnW0GQR1XS
YAPC	NVfzOJVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3sToZKSzVyPUS5NE43KG6P	MWXTRW5ITVJ?
LS-1034	M4\TU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfPTWM2OD12OUGuNFYhdk1?	MoXWV2FPT0WU
RCM-1	NUfObJh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTR7Nj62PEBvVQ>?	NFjZSlNUSU6JRWK=
HCC1954	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrLcFd3UUN3ME21NVIvPSCwTR?=	M3nqcXNCVkeHUh?=
SK-MEL-24	NUT4cppXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTVzNj61NUBvVQ>?	MoPkV2FPT0WU
NB12	NV:4dnRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3jUmFKSzVyPUWyPE41OiCwTR?=	MWfTRW5ITVJ?
SW756	M1jTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XnfGlEPTB;NUW0Mlk3KG6P	NUTBcYd7W0GQR1XS
HCC1187	Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\sTWM2OD13N{WuPFMhdk1?	MnjhV2FPT0WU
NCI-H2342	MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPoNGRKSzVyPUW5NE4{QSCwTR?=	NIHEcWZUSU6JRWK=
NCI-H2291	Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTV7OD6zNUBvVQ>?	MYfTRW5ITVJ?
OVCAR-3	NV7RTVQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTV7OD65OkBvVQ>?	MoHEV2FPT0WU
MHH-NB-11	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTZ{OT6wNUBvVQ>?	NV3Ed\|BSW0GQR1XS
SAS	NU\HRVV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHyUVdTUUN3ME22OVIvPjdibl2=	NILMfo1USU6JRWK=
COLO-824	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUOySJEzUUN3ME22PFkvOzdibl2=	NIrpbopUSU6JRWK=
HCC1395	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn2yTWM2OD14OUiuOUBvVQ>?	M{e3XXNCVkeHUh?=
COLO-668	M{PZVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTdyNj6xJI5O	Mn7FV2FPT0WU
NCI-H226	Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTtTWM2OD15MEeuPEBvVQ>?	NVrwSW4zW0GQR1XS
NB17	NX\aUXVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXXTWM2OD15MkGuO\|Uhdk1?	MXrTRW5ITVJ?
SW1463	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlG0TWM2OD15M{muNVkhdk1?	MkTFV2FPT0WU
TGW	M2T0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{j6OmlEPTB;N{[wMlE2KG6P	NFHwNHRUSU6JRWK=
NCI-H526	NYr2S4tsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPTTWM2OD16MkOuOVMhdk1?	MVnTRW5ITVJ?
COR-L88	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\yTWM2OD16NEiuNVIhdk1?	MXzTRW5ITVJ?
NCI-H441	NFTEeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DNfmlEPTB;OEm1MlIzKG6P	Mo\CV2FPT0WU
NCI-H630	NX7aeYNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPVOlZpUUN3ME25NVIvQTZibl2=	MnHjV2FPT0WU
Mo-T	NFnPWWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TOb2lEPTB;OUS3Mlg5KG6P	M1HiW3NCVkeHUh?=
JAR	NHXWN4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTWTWM2OD17NU[uNlQhdk1?	MnHhV2FPT0WU
NCI-H1838	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTFwMEKzPFgh\|ryP	MoD3V2FPT0WU
DoTc2-4510	MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHOTWM2OD1zLkC3N\|c3KM7:TR?=	NIPiWIRUSU6JRWK=
MKN28	Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4f3emlEPTB;MT6wPVAzPCEQvF2=	MX;TRW5ITVJ?
HuP-T3	NVLIWVhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2G0bmlEPTB;MT6xNVkxPSEQvF2=	M1zIbHNCVkeHUh?=
TE-9	MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vw[mlEPTB;MT6xNlk4OyEQvF2=	NGXqfo5USU6JRWK=
NY	MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlP5TWM2OD1zLkG2O\|kzKM7:TR?=	NHW4cWRUSU6JRWK=
HT55	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\Ne2lEPTB;MT6zNVM1PCEQvF2=	M{CyS3NCVkeHUh?=
SW837	NYfxVXBKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Moe1TWM2OD1zLkOyPVc5KM7:TR?=	NVvxXHoyW0GQR1XS
NCI-H2029	NHHEU4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoX2TWM2OD1zLkSxO\|kyKM7:TR?=	NVGwd3N1W0GQR1XS
IST-SL1	M4TLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGX6T5JKSzVyPUGuOFQzPCEQvF2=	M{TpTnNCVkeHUh?=
COLO-741	M13uSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWm5WoNnUUN3ME2xMlQ6PzdzIN88US=>	MnrEV2FPT0WU
LU-65	Mlj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknQTWM2OD1zLk[yNlQ6KM7:TR?=	MkG1V2FPT0WU
NCI-H1304	MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3y1SWlEPTB;MT62OVQ6QCEQvF2=	MVrTRW5ITVJ?
KARPAS-299	Mki1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTFwN{m0O\|kh\|ryP	NX34dXVXW0GQR1XS
NCI-H358	MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLkTWM2OD1zLkm1OVA{KM7:TR?=	M37rT3NCVkeHUh?=
OAW-28	NFXHbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LvXGlEPTB;Mj6wOlkyQSEQvF2=	MlzYV2FPT0WU
C8166	M3jROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTJwNkOzPVIh\|ryP	MmnuV2FPT0WU
COLO-678	NV\Q[4VlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jiXmlEPTB;Mj64N\|c3QCEQvF2=	NI\Z[3RUSU6JRWK=
SK-N-DZ	NU\4PYx[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoW4TWM2OD1{Lki2N\|gyKM7:TR?=	Mn;3V2FPT0WU
NCI-H82	MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2W4VGlEPTB;Mj65NFM3QSEQvF2=	M3fmdHNCVkeHUh?=
JVM-2	MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3YTWM2OD1\|LkCzNVg5KM7:TR?=	MXHTRW5ITVJ?
SW1116	Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjoO3VpUUN3ME2zMlA2PDFzIN88US=>	NULCTI16W0GQR1XS
MDA-MB-453	NUjXSGNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Moj5TWM2OD1\|LkGwOFM6KM7:TR?=	M3O1cXNCVkeHUh?=
Calu-6	M3nCVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnxTWM2OD1\|LkG5PVch\|ryP	M{PqTXNCVkeHUh?=
SHP-77	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrYc2tQUUN3ME2zMlUzQCEQvF2=	NEfWd4NUSU6JRWK=
Capan-2	NWHkPY8yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\HS2lEPTB;ND6zNlU5OSEQvF2=	NFXBWVNUSU6JRWK=
SW948	Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkn2TWM2OD12Lke0O\|c6KM7:TR?=	NGO3VI5USU6JRWK=
HDLM-2	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXFXms4UUN3ME21MlA4PzJ3IN88US=>	MYfTRW5ITVJ?
LAN-6	NXzKdplFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;WdlRKSzVyPU[uNlE1QTVizszN	NWfPcGJ4W0GQR1XS
LU-135	NI[4ZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LYc2lEPTB;Nj60N\|A4PyEQvF2=	MmrnV2FPT0WU
T84	MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTIVoRKSzVyPU[uPVg3PCEQvF2=	NGHJb\|ZUSU6JRWK=
CAPAN-1	MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnDW45WUUN3ME23MlYzOjN\|IN88US=>	NXW2[4JCW0GQR1XS
SW1417	M1znXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDXSo5KSzVyPUeuPVE4OzFizszN	Ml;ZV2FPT0WU
BALL-1	M12zdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHOU4xKSzVyPUiuOVA1ODlizszN	NHfXO5VUSU6JRWK=
HT-29	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYntWG5oUUN3ME25MlA4PTl7IN88US=>	M4f2XHNCVkeHUh?=
C3A	NFPjR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;EcINPUUN3ME25Mlg5Ozl2IN88US=>	NF\qSnhUSU6JRWK=
NCI-H1993	NYridXROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVmyeVRHUUN3ME2xNE42ODhzIN88US=>	MoXJV2FPT0WU
SK-MEL-1	NFPvUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HPOmlEPTB;MUGuOlI5QSEQvF2=	NXnWb3oxW0GQR1XS
DU-145	M3;4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTF2LkWwOVIh\|ryP	NEXpNpVUSU6JRWK=
KP-N-YN	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTKdmtKSzVyPUG0MlUyODNizszN	M3nnfXNCVkeHUh?=
CCRF-CEM	NWLXS25qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTF2Lke4NFkh\|ryP	NHjYTIFUSU6JRWK=
ZR-75-30	MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rqR2lEPTB;MU[uN\|MxOyEQvF2=	M3vPUXNCVkeHUh?=
A673	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4e5U2lEPTB;MkCuOVUxPyEQvF2=	MoXLV2FPT0WU
K-562	NUW1R\|VET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTJ6LkSxPFMh\|ryP	NVzpRVkzW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Myc / Vinculin / pT58 Myc; PubMed: 25934076 Cancer Discov Immunoblots documenting MYC and pT58 MYC stability. SW480 cells were treated with 200nM BEZ235 or solvent control for 24h and cycloheximide (50µg/ml) and harvested at the indicated time points. Vinculin was used as loading control. Exposures of MYC and pT58 MYC blots were adjusted to equalize exposure at 0 min (n=3; unless otherwise indicated, n indicates the number of independent biological repeat experiments in the following legends). pAkt / Akt / Skp2 / AR / pS6 / p27; PubMed: 24347472 Prostate BEZ235 decreases Skp2 and increases AR protein expression inC4-2B cells. Cells were treated with BEZ235 at various doses. Cell lysates were subjected to Westernblot analysis with indicated antibodies. p-S6K / S6K / p-Akt / Akt / p-ABL / BCR-ABL; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the phosphorylation levels of S6K, Akt (Ser473), and BCR–ABL in CML cells. Results of Western blot. Bcl-2 / Caspase-3 / Cleaved caspase-3 ; PubMed: 28435223 Drug Des Devel Ther K562 (A1) and KBM7R (A2) cells were treated with BEZ235 for 24 h; total protein lysates were immunoblotted with antibodies for Bcl-2, caspase-3, and cleaved caspase-3. Cyclin D1 / Cyclin D2 ; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the expression levels of cyclin D1 and cyclin D2 in K562 and KBM7R cells. Western blot results of K562 (A1) and KBM7R (A2) cells. mTOR / p-mTOR / p70S6K / p-p70S6K ; PubMed: 29581778 J Cancer Eca-109 cells was treated with increasing concentration of BEZ235 (0, 100, 200 and 500 nM) for 48 hours. Western blot showed the inhibition effect of PI3K/mTOR pathway was dose dependent. p-EGFR-Tyr1068 / EGFR / p-HER2-Tyr1221 / p-HER2-Tyr1222 / HER2 / p-HER3-Tyr1289; PubMed: 21278786 Oncogene Immunoblots of protein lysates from BT474 and MCF7-HER2 cells treated with either BEZ235 alone (0–500 n) or the combination of BEZ235 (0–500 n) and the tyrosine kinase inhibitor lapatinib (LAP, 500 n) for 24 h.	25934076 24347472 28435223 29581778 21278786
Immunofluorescence	SP1; PubMed: 26336820 Oncotarget Immunofluorescence assessment of SP1 after BEZ235 treatment for 24 hrs in A673, SKNMC cells and in HFF. p-ErbB2(Y1248); PubMed: 24675532 Cell Res Immunofluorescence staining of BT474.LapR cells grown in 3-D culture under different treatment conditions for a week. Scale bar indicates 50 μm. LC3; PubMed: 23603977 Acta Pharmacol Sin (A) SU-2 cells were treated with NVP-BEZ235 (10 nmol/L) for 12 h and then harvested 24 h after treatment with IR (8 Gy), and analyzed for LC3 expression (top) or the formation of autophagolysosomes by using MDC (middle) and LTR (bottom) by immunofluorescence analysis (600×magnification).	26336820 24675532 23603977
Growth inhibition assay	Cell viability (P3, U87); PubMed: 27542970 BMC Cancer IC50 doses of dactolisib for P3 (left) and U87 (right) glioma cells, generated from MTS assay. Cell viability (breast cancer cells); PubMed: 28060760 Oncotarget Cell viability of breast cancer cells treated by either BEZ235 or TSA for 48h was measured by MTT assay. Each cell line was analyzed in triplicate, and a representative experiment is shown. Cell viability (K562, KBM7R); PubMed: 28435223 Drug Des Devel Ther (A) K562 cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (B) KBM7R cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (C) K562 cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. (D) KBM7R cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. Mean ± SD. n=3. *P<0.05, compared to the control group. #P<0.05, compared to the group of IM alone.	27542970 28060760 28435223
ELISA	VEGF; PubMed: 19671762 Mol Cancer Ther NVP-BEZ235 attenuated VEGF secretion by at least 40% in U87 cells. The VEGF level in the serum-free medium was measured in triplicate and the experiment repeated at least twice to confirm results.	19671762

In vivo

BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro Protein Kinase, PI3K, and mTOR Assays: PI3Kα, β, and δ proteins are composed of the iSH2 domain of p85 NH₂-terminally fused to the full-length protein p110 protein, with the exception of α that also does not contain the last 20 amino acids. PI3Kγ is produced as full-length protein deleted for its first 144 amino acids. All constructs are fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue-Bac4.5 (for α, β, and δ isoforms) or pVL1393 (for γ isoform) plasmids. The different vectors are then cotransfected with BaculoGold WT genomic DNA using methods recommended by the vendor for production of the respective recombinant baculoviruses and proteins. BEZ235 are tested for their activity against PI3K using a Kinase-Glo assay. The kinase reaction is done in 384-well black plate. Each well is loaded with 50 μL of test items (in 90% DMSO) and 5 μL reaction buffer containing 10 μg/mL PI substrate (l-α-phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-glucoside) and the PI3K proteins (10, 25, 10, and 150 nM of p110α, p110β, p110δ, and p110γ, respectively) are then added to it. The reaction is started by the addition of 5 μL of 1 μM ATP prepared in the reaction buffer and is incubated for either 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ). It is terminated by the addition of 10 μL Kinase-Glo buffer. The plates are then read in a Synergy 2 reader for luminescence detection.
Cell Research: ^[2]	- Collapse Cell lines: HCT116, DLD-1 and SW480 cells Concentrations: 0-1 μM Incubation Time: 48 hours Method: The human CRC cell lines, HCT116 (PIK3CA mutant; kinase domain at H1047R), DLD-1 (PIK3CA mutant; helical domain at E545K), and SW480 (PIK3CA wild-type) and isogenic DLD-1 PIK3CA mutant as well as wild-type cells are maintained in DMEM with 10% FBS and 1 × Penicillin/Streptomycin. Cells are plated at different initial densities (HCT116: 3 × 10³ cells/well, DLD-1: 5.5 × 10³ cells/well, SW480: 4.5 × 10³ cells/well, DLD-1 PIK3CA mutant: 7 × 10³ cells/well, and DLD-1 PIK3CA wild-type: 9 × 10³ cells/well) to account for differential growth kinetics. After 16 hours, cells are incubated with increasing concentrations of BEZ235, and the drug-containing growth medium is changed every 24 hours. Cell viability is assessed 16 hours after the initial plating and 48 hours after initiation of drug treatment using the colorimetric MTS assay CellTiter 96® AQueous One Solution Cell Proliferation Assay, as per the manufacturer's instructions. Cell viability after drug treatment is normalized to that of untreated cells also grown for 48 hours. For western blot analysis, cells are plated with zero or maximum inhibitory dose (500 nM) BEZ235 for 2, 6, 24, or 48 hours. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Female Harlan athymic nude mice Dosages: 45 mg/kg Administration: p.o. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMF	18 mg/mL warmed (38.33 mM)
	DMSO	0.01 mg/mL (0.02 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): NMP+PEG300 (10+90, v+v) For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dactolisib (BEZ235) SDF

Molecular Weight	469.55
Formula	C₃₀H₂₃N₅O
CAS No.	915019-65-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	NVP-BEZ235

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01856101	Terminated	Drug: BEZ235	Carcinoma Transitional Cell	Cliniques universitaires Saint-Luc- Université Catholique de Louvain\|Novartis	February 2013	Phase 2
NCT01717898	Terminated	Drug: BEZ235\|Drug: Prednisone\|Drug: Abiraterone acetate	Castrate-resistant Prostate Cancer	Charles Ryan\|Novartis Pharmaceuticals\|University of California San Francisco	January 31 2013	Phase 1\|Phase 2
NCT01756118	Unknown status	Drug: BEZ235	Acute Lymphoblastic Leukemia\|Leukemia Myelocytic Acute\|Chronic Myelogenous Leukemia With Crisis of Blast Cells	Johann Wolfgang Goethe University Hospital	June 2012	Phase 1
NCT01290406	Withdrawn	Drug: BEZ235	Endometrial Cancer	Novartis Pharmaceuticals\|Novartis	March 2012	Phase 2
NCT01288092	Withdrawn	Drug: BEZ235	Metastatic Breast Cancer	Novartis Pharmaceuticals\|Novartis	March 2012	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
With difficulties in dissolving BEZ235, How can I improve its solubility?
Answer:
For in vivo study, we suggest the vehicle solution NMP/polyethylene glycol 300 (10/90, v/v). Please dissolve BEZ235 in NMP as more as possible. You can sonicate and warm it in water bath for a while. Then dilute with PEG 300.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Selective PI3K Inhibitors

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
Selective PI3K Inhibitors

TGX-221 : p110β-specific, IC50=5 nM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Wortmannin

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Dactolisib (BEZ235)